New drug cocktail targets tough pancreatic tumors
NCT ID NCT07619521
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether combining two drugs—selumetinib and DS-8201a—can safely shrink or control advanced pancreatic cancer that has a specific genetic change (KRAS mutation) and a protein called HER2. About 31 adults with cancer that cannot be removed by surgery or has spread will take part. The goal is to find the best dose and see if the combination helps stop tumor growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy cocktail slow pancreatic cancer? a new trial aims to find out.
- Smart drug delivers chemo directly to pancreatic cancer cells
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
- Can a tailored web portal help pancreatic cancer patients exercise and eat better during chemotherapy?
- Could a stomach drug help fight pancreatic cancer?